About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

PF-00489791 For The Treatment Of Raynaud's | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT01090492

PF-00489791 For The Treatment Of Raynaud's

The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Rayna...

Lead sponsor: Pfizer•23 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Pfizer

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Active Raynaud's Phenomenon
•Stable disease and medication requirements over the previous two months
•For Secondary Raynaud's Phenomenon subjects, a diagnosis of scleroderma using the American College of Rheumatology criteria or by the presence of at least 3/5 features of CREST syndrome
•both sexes

Exclusion Criteria

•Uncontrolled hypertension, diabetes mellitus, angina, or using oral nitrates
•Smoking within 3 months or smoking cessation using nicotine products
•Subjects currently taking sildenafil, tadalafil or vardenafil
•Subjects with ulnar arterial occlusive disease as shown by a modified Allen test
•Pregnant or breast feeding or considering pregnancy in next 4 months
•Participation in trial for investigational drug within 30 days

Related studies

MRI Guided Management of Occlusive Peripheral Arterial Disease

NCT06782100 · Peripheral Vascular Diseases

RECRUITINGPhase 3

A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE)

NCT06656988 · Peripheral Vascular Diseases, Kidney Diseases

Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform

NCT04927156 · Intracranial Aneurysm, Brain Arterial Disease, and more

RECRUITINGPhase 3

Improving Mobility After Revascularization in Peripheral Artery Disease

NCT06686121 · Peripheral Artery Disease, Intermittent Claudication, and more

RECRUITINGPhase 2

Fisetin to Reduce Senescence and Mobility Impairment in PAD

NCT06399809 · Peripheral Arterial Disease, Aging, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 16, 2018Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment243

Start dateAug 2010

Last updatedMay 16, 2018

Condition

Raynaud's Disease Peripheral Vascular Disease

Locations shown

Stanford Hospital and Outpatient Center

Redwood City, California

University of Connecticut Health Center

Farmington, Connecticut

Georgetown University Hospital

Washington D.C., District of Columbia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 16, 2018Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions